全球生物製藥和疫苗製造市場規模（按產品類型、技術、應用、區域範圍和預測）

生物製藥和疫苗製造市場規模和預測

過去幾年，生物製藥和疫苗製造市場規模以中等速度成長，成長率相當高，預計在預測期內，即 2026-2032 年，市場規模將大幅成長。

生物製藥和疫苗生產的全球市場驅動力

生物製藥和疫苗製造市場的市場促進因素可能受到多種因素的影響，其中包括：

感染疾病的增加：肝炎、COVID-19、流感、人類乳突病毒 (HPV) 等感染疾病的盛行率上升，推動了對疫苗和生物製藥的需求。在全球範圍內，各國政府和醫療保健組織正在優先開展疫苗宣傳活動和藥物研究舉措，以對抗這些疾病，從而推動市場擴張。

生物製藥需求日益成長：生物製藥為多種疾病（包括癌症、自體免疫疾病和感染疾病）提供針對性和個人化的治療方案。這些治療方法包括單株抗體、重組蛋白、疫苗和細胞療法。生物製藥需求的不斷成長正在推動對基礎設施和生產能力的投資。

製造流程的技術進步：由於一次性系統、連續生產和自動化等生物加工技術的發展，生物製藥和疫苗的生產變得更有效率、可擴展且成本更低。這些技術進步縮短了生產時間，並提高了生產效率，從而推動了生物製藥和疫苗的發展。

良好的法規環境已然形成，歐洲藥品管理局（EMA）和美國食品藥物管理局（FDA）等機構為疫苗和生物製藥的生產提供指導和協助。更快捷的核准流程、優惠的法規和獎勵，都有助於鼓勵對技術和工業設施的投資。

生技的應用不斷拓展：疫苗和生物製藥的研發、生產和發現都高度依賴生技。基因工程、細胞培養技術和生物資訊學的進步推動並促進了各種疾病的創新治療方法和疫苗的開發。

全球衛生計劃和疫苗接種計劃：預防和控制感染疾病的疫苗接種計劃和全球衛生計劃得到了官民合作關係、國際組織和政府舉措的支持，為生物製藥和疫苗製造商擴大產品線和進入新市場提供了機會。

疫情防治與因應：像 COVID-19 疫情這樣的情況凸顯了採取快速應對和防控措施的重要性。為了因應新興感染疾病的風險，各國政府和醫療機構優先投資於疫苗研發和生產基礎設施，這推動了市場需求。

增加研發支出：為了發現和創造新的生物藥物和疫苗，製藥公司、生技公司和學術機構正在投入大量資源進行研發。創新、產品線開發和產品開發均由研發投資驅動。

人口老化：隨著人口老化，人們更容易感染感染疾病和慢性病，疫苗和生物製藥的需求也隨之增加。隨著全球人口老化，治療和預防生技藥品的市場正在不斷擴大。

新興市場：疫苗和生物製藥製造業在新興經濟體，尤其是拉丁美洲和亞太地區，擁有巨大的成長潛力。醫療成本的上漲、醫療基礎設施的建設以及疾病負擔的增加，正在推動這些地區的市場擴張。

限制全球生物製藥和疫苗製造市場的因素

生物製藥和疫苗製造市場可能面臨多種限制和挑戰，包括：

高昂的開發和生產成本：生物製藥和疫苗的研發、生產設施和設備必須預先購買。高昂的成本可能會阻礙小型公司和新興企業進入市場，從而降低競爭和創新能力。

複雜的製造步驟：細胞培養、發酵和精製只是用於生產生物製藥和疫苗的先進生物技術步驟中的幾個步驟。與普通藥物相比，這些技術需要專門的工具、知識和品管程序，從而導致更高的生產成本和更長的前置作業時間。

監管要求與合規性：歐洲藥品管理局 (EMA) 和美國食品藥物管理局(FDA) 等衛生機構對疫苗和生物製藥的生產實施嚴格的監管控制。對於新產品和生產設施而言，滿足產品品質、安全性和有效性的監管標準可能既昂貴又耗時。

專利保護和智慧財產權：生物製藥和疫苗產業的特點是擁有強大的專利保護和智慧財產權。專利獨佔期為創新產品提供了市場獨佔權，並防止學名藥和生物相似藥競爭對手的競爭。然而，專利到期也會導致品牌產品競爭加劇，價格下降。

供應鏈脆弱性：疫情、天災和地緣政治不穩定等事件可能會擾亂生物製藥和疫苗生產的全球供應鏈。供應鏈中斷可能導致關鍵物資、機械和零件短缺，進而影響產量和產品供應。

市場准入和報銷挑戰：分銷網路、醫療基礎設施以及定價和報銷政策限制了某些地區生物製藥和疫苗的獲取。市場進入問題可能會影響創新產品的開發和應用，尤其是在資源匱乏的新興經濟體。

技術複雜性與創新風險：隨著精製方法、反應器設計和細胞株開發的突破，用於生產疫苗和生物製藥的技術不斷變化。投資新技術和創新存在固有風險，包括可擴展性問題、監管不確定性和技術難題。

產品生命週期管理：藥物安全檢測、產品監管和上市後監管是管理生物製藥和免疫產品生命週期所需的持續投資。在產品生命週期中，生產流程、監管要求和產品配方的變更可能需要昂貴的升級和修訂。

安全與品質保證：確保生物製藥和疫苗的效力、安全性和純度對公共衛生至關重要。批次測試、驗證流程和品管技術對於維護產品品質至關重要。

目錄

第1章全球生物製藥和疫苗製造市場簡介

• 市場概覽
• 研究範圍
• 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

• 資料探勘
• 驗證
• 第一手資料
• 資料來源列表

第4章全球生物製藥與疫苗製造市場展望

• 概述
• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 波特五力模型
• 價值鏈分析

第5章全球生物製藥和疫苗製造市場（依產品類型）

• 概述
• 疫苗
• 生物製藥

6. 全球生物製藥和疫苗製造市場（依最終用途）

• 感染疾病
• 腫瘤學
• 自體免疫疾病
• 代謝紊亂

7. 全球生物製藥和疫苗製造市場（按技術）

• 上游流程
• 下游工藝
• 一次性使用系統
• 常規製造

8. 全球生物製藥和疫苗製造市場（按地區）

• 概述
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 其他
  • 拉丁美洲
  • 中東和非洲

第9章全球生物製藥與疫苗製造市場：競爭格局

• 概述
• 各公司市場排名
• 重點發展策略

第10章 公司簡介

• Novartis
• Pfizer
• Sanofi
• Roche
• Abbott
• Regeneron Pharmaceuticals
• Alexion Pharmaceuticals
• Johnson and Johnson
• GlaxoSmithKline
• Merck

第11章 附錄

• 相關調查

Biopharmaceutical And Vaccine Production Market Size And Forecast

Biopharmaceutical And Vaccine Production Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2026 to 2032.

Global Biopharmaceutical And Vaccine Production Market Drivers

The market drivers for the Biopharmaceutical And Vaccine Production Market can be influenced by various factors. These may include:

Growing Incidence of Infectious Diseases: The need for vaccinations and biopharmaceuticals is driven by the rising prevalence of infectious diseases, including hepatitis, COVID-19, influenza, and human papillomavirus (HPV). Globally, governments and healthcare institutions provide priority to immunization campaigns and medication research initiatives in an attempt to combat these illnesses, which drives market expansion.

Growing Need for Biopharmaceuticals: Biopharmaceuticals provide targeted and individualized therapy choices for a range of ailments, including cancer, autoimmune disorders, and infectious diseases. Examples of these treatments include monoclonal antibodies, recombinant proteins, vaccines, and cell therapies. Infrastructure and production capacity are being invested in due to the rising demand for biopharmaceuticals.

Technological Progress in manufacture Processes: The manufacture of biopharmaceuticals and vaccines is becoming more efficient, scalable, and affordable thanks to ongoing developments in bioprocessing technologies, such as single-use systems, continuous manufacturing, and automation. These developments shorten production schedules and increase productivity, which propels market expansion.

A supportive regulatory environment is created by organizations like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), which offer direction and assistance in the creation of vaccines and biopharmaceuticals. Accelerated approval processes, favorable regulations, and incentives all work to promote investment in technology and industrial facilities.

Increasing the Uses of Biotechnology: The development, manufacture, and discovery of vaccines and biopharmaceuticals all depend heavily on biotechnology. The creation of innovative treatments and vaccines for a variety of diseases is made possible by developments in genetic engineering, cell culture technology, and bioinformatics, which propels market growth.

Global Health Initiatives and Vaccination Programs: In order to prevent and manage infectious diseases, vaccination programs and global health initiatives are supported by public-private partnerships, international organizations, and government initiatives. These initiatives give biopharmaceutical and vaccine producers the chance to grow their product lines and penetrate new markets.

Pandemic Preparedness and Response: Situations like the COVID-19 pandemic emphasize the significance of having both quick response and preparedness measures in place. To address new infectious dangers, governments and healthcare institutions prioritize expenditures in vaccine development and production infrastructure, which drives demand in the market.

Growing Research and Development Expenditure: To find and create novel biopharmaceuticals and vaccines, pharmaceutical corporations, biotechnology businesses, and academic institutions devote a large amount of their resources to research and development (R&D). Innovation, pipeline development, and market growth are all fueled by R&D investments.

Growing Aging Population: As people age, they become more vulnerable to infectious and chronic illnesses, which increases the need for vaccinations and biopharmaceuticals. The market for therapeutic and preventive biologics is growing as the world's population ages.

Emerging Markets: The manufacturing of vaccines and biopharmaceuticals has enormous growth potential in emerging economies, especially those in Latin America and Asia-Pacific. Market expansion in these regions is driven by rising healthcare costs, bettering healthcare infrastructure, and an increase in the burden of disease.

Global Biopharmaceutical And Vaccine Production Market Restraints

Several factors can act as restraints or challenges for the Biopharmaceutical And Vaccine Production Market. These may include:

High Development and Production Costs: Research and development (R&D), production facilities, and equipment must be purchased up front in order to create and manufacture biopharmaceuticals and vaccines. Expensive expenses may prevent smaller businesses and startups from entering the market, which would reduce competition and innovation.

Complex Manufacturing Procedures: Cell culture, fermentation, and purification are only a few examples of the sophisticated biotechnological procedures used in the production of biopharmaceuticals and vaccines. In comparison to typical pharmaceuticals, these techniques have greater manufacturing costs and longer lead times since they need specialized tools, knowledge, and quality control procedures.

Regulatory Requirements and Compliance: Health authorities like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) impose strict regulatory control on the manufacture of vaccines and biopharmaceuticals. For new products or production facilities in particular, meeting regulatory criteria for product quality, safety, and efficacy can be expensive and time-consuming.

Patent Protection and Intellectual Property Rights: The biopharmaceutical and vaccine industries are distinguished by robust patent protection and intellectual property rights. Patent exclusivity periods give innovative products market exclusivity, preventing generic or biosimilar competitors from undercutting them. On the other hand, heightened competition and declining prices for branded goods may result from patent expiration.

Supply Chain Vulnerabilities: Events like pandemics, natural catastrophes, and geopolitical unrest have the potential to disrupt the world's supply chain for the production of biopharmaceuticals and vaccines. Supply chain disruptions can result in shortages of vital supplies, machinery, and parts, which can impact output and product availability.

Market Access and Reimbursement Challenges: Due to distribution networks, healthcare infrastructure, and price and reimbursement policies, access to biopharmaceuticals and vaccines may be restricted in some areas. Adoption and uptake of innovative products can be impacted by market access issues, especially in developing economies where resources are scarce.

Technological Complexity and Innovation Risks: Technologies used in the manufacture of vaccines and biopharmaceuticals are always changing due to breakthroughs in purification methods, bioreactor design, and cell line development. There are inherent risks associated with investing in new technologies and innovation, such as scalability concerns, regulatory uncertainties, and technological difficulties.

Product Lifecycle Management: Pharmacovigilance, product stewardship, and post-market surveillance are continuous investments needed to manage the lifecycle of biopharmaceutical and vaccination products. Over the course of the product lifespan, expensive upgrades and revisions may be required due to changes in manufacturing procedures, regulatory requirements, or product formulas.

Safety and Quality Assurance: It is crucial for public health to guarantee the potency, safety, and purity of biopharmaceuticals and vaccinations. To maintain product quality, batch testing, validation processes, and quality control techniques are crucial.

Global Biopharmaceutical And Vaccine Production Market Segmentation Analysis

The Global Biopharmaceutical And Vaccine Production Market is Segmented on the basis of Product Type, Technology, Application, and Geography.

Biopharmaceutical And Vaccine Production Market, By Product Type

• Biopharmaceuticals: Includes therapeutic proteins (such as monoclonal antibodies, hormones, cytokines, and growth factors), vaccines, recombinant proteins, nucleic acid-based therapeutics (such as RNA and DNA vaccines), and cell-based therapies (such as stem cell therapies and CAR-T cell therapies).
• Vaccines: Includes prophylactic vaccines (for prevention of infectious diseases) and therapeutic vaccines (for treatment of diseases such as cancer and chronic infections).

Biopharmaceutical And Vaccine Production Market, By Technology

• Upstream Processing: Includes cell culture, fermentation, and cell expansion techniques for the production of biopharmaceuticals and vaccines in bioreactors or cell culture systems.
• Downstream Processing: Includes purification, separation, and recovery techniques for isolating and purifying biopharmaceuticals and vaccines from cell culture supernatants or fermentation broths.
• Single-Use Systems: Utilizes disposable bioprocessing equipment and consumables for biopharmaceutical and vaccine production, offering flexibility, scalability, and reduced risk of contamination.
• Continuous Manufacturing: Utilizes continuous bioprocessing techniques, such as perfusion cell culture and continuous chromatography, for more efficient and cost-effective production of biopharmaceuticals and vaccines compared to traditional batch processing.

Biopharmaceutical And Vaccine Production Market, By Application

• Infectious Diseases: Includes vaccines and therapeutics for prevention and treatment of infectious diseases such as influenza, COVID-19, hepatitis, human papillomavirus (HPV), and HIV/AIDS.
• Oncology: Includes biopharmaceuticals and vaccines for treatment of cancer, including monoclonal antibodies, cancer vaccines, and cell-based immunotherapies.
• Autoimmune Disorders: Includes biopharmaceuticals for treatment of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease.
• Metabolic Disorders: Includes biopharmaceuticals for treatment of metabolic disorders such as diabetes and obesity.
• Neurological Disorders: Includes biopharmaceuticals for treatment of neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
• Other Therapeutic Areas: Includes biopharmaceuticals and vaccines for treatment of cardiovascular diseases, respiratory diseases, rare diseases, and genetic disorders.

Biopharmaceutical And Vaccine Production Market, By Geography

• North America: Includes the United States and Canada, characterized by a strong biopharmaceutical industry, robust R&D infrastructure, and significant investments in vaccine development and production.
• Europe: Includes countries such as Germany, the UK, France, Italy, and Spain, with a well-established biopharmaceutical sector and leading vaccine manufacturers.
• Asia-Pacific: Includes China, Japan, India, South Korea, and Australia, where the biopharmaceutical and vaccine production market is rapidly expanding due to government initiatives, growing healthcare infrastructure, and increasing R&D investments.
• Latin America: Includes Brazil, Mexico, and other countries in Central and South America, with a growing demand for biopharmaceuticals and vaccines driven by population growth, disease burden, and government healthcare initiatives.
• Middle East and Africa: Includes countries such as Saudi Arabia, UAE, South Africa, and others, where the biopharmaceutical and vaccine production market is growing due to increasing healthcare expenditure, disease prevalence, and investments in pharmaceutical manufacturing.

Key Players

• The major players in the Biopharmaceutical And Vaccine Production Market are:
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Johnson & Johnson
• Novartis International AG
• Pfizer Inc.
• Eli Lilly and Company
• Abbott Laboratories
• GlaxoSmithKline plc
• Amgen Inc.
• Sanofi S.A.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Vaccine
• 5.3 Biopharmaceutical

6 GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET, BY END-USE

• 6.1 Infectious Diseases
• 6.2 Oncology
• 6.3 Autoimmune Disorders
• 6.4 Metabolic Disorders

7 GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET, BY TECHNOLOGY

• 7.1 Upstream Processing
• 7.2 Downstream Processing
• 7.3 Single-Use Systems
• 7.4 Continuous Manufacturing

8 GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET: GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 The U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 The U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 The Middle East and Africa

9 GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET: COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Novartis
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Pfizer
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Sanofi
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Roche
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Abbott
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Regeneron Pharmaceuticals
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.8 Alexion Pharmaceuticals
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.8 Johnson and Johnson
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.10 GlaxoSmithKline
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments
• 10.10 Merck
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research